This library exists to say what a compound is. For orforglipron the most useful sentence is a negative one: it is not a peptide, and the reason it is here at all is that almost everyone who looks it up believes it is.
What it actually is
Orforglipron is a synthetic organic molecule — formula C₄₈H₄₈F₂N₁₀O₅, molecular weight 883.0, PubChem CID 137319706, development code LY3502970. It has no amino acid residues, no peptide bonds and no sequence to write down. Where the rest of this library's metabolic entries are chains of residues, this is a single designed molecule of the kind a chemist would recognise as an ordinary small-molecule drug.
What it shares with the peptides is a destination. The GLP-1 receptor is a docking site on the surface of certain cells; the body's own GLP-1 — 31 residues, cut out of proglucagon — is what normally occupies it. Semaglutide is a modified version of that peptide, built to survive long enough to be injected weekly. Orforglipron arrives at the same receptor from a completely different chemical direction.
| Semaglutide | Orforglipron | |
|---|---|---|
| Chemical class | Modified peptide | Small molecule |
| Molecular weight | ~4,114 Da | 883 Da |
| Amino acid residues | 31 (modified) | none |
| Route | Injection (and one oral formulation) | Oral tablet |
| Target | GLP-1 receptor | GLP-1 receptor |
At roughly a fifth of the mass, it does the same job at the same lock.
Why the chemistry decides the dosing
A peptide taken by mouth meets the machinery that exists specifically to break chains of amino acids apart. That is the single hardest problem in this drug class, and it is why nearly every GLP-1 medicine is an injection. The one peptide in the class with an oral form needs an absorption enhancer and a strict routine — empty stomach, small sip of water, wait — to get a usable fraction of the dose past the stomach.
A small molecule has none of that trouble. It can be a plain daily tablet. That difference propagates a long way: no cold chain, no needles, no injection-device manufacturing, and a supply chain that looks like ordinary pharmaceutical chemistry rather than like peptide synthesis. Whether it works as well is a question for the trials; that it is easier to make and take is a property of what it is made of.
Our entry on what a peptide actually is covers why "peptide" describes chemistry and not effect. Orforglipron is the cleanest available demonstration that the reverse is also true: the same effect, without the chemistry.
The programme, counted
On 2026-09-16, ClinicalTrials.gov held 53 interventional studies naming orforglipron, with 33,058 participants between them.
| Phase | Studies |
|---|---|
| Phase 3 | 27 |
| Phase 1 | 21 |
| Phase 2 | 3 |
| Phase 4 | 2 |
Most entries in this library report registry counts in the single digits, and many report zero. This is a different category of thing — a full late-stage pharmaceutical programme, and one of the largest attached to any molecule covered here.
It is also a single-company programme. Eli Lilly sponsors 49 of the 53. The other four are investigator-initiated: two at Massachusetts General Hospital, one at the University of Florida, one from Innovent Biologics. That is ordinary for a drug still under patent, and it does mean the central results have not yet been reproduced by anyone with no stake in them.
What is being studied, beyond weight
Obesity and overweight dominate the condition list, with type 2 diabetes behind them. But the phase 3 records reach considerably further:
- Cardiovascular outcomes — a recruiting study with a planned enrolment of 7,140, the largest in the programme
- Obstructive sleep apnoea — 712 participants
- Stress urinary incontinence in women — 1,000 participants
- Hypertension
- Adolescent and paediatric obesity — including a platform trial for children
And the programme runs direct comparisons rather than only placebo studies: registered head-to-head trials against semaglutide (1,698 participants) and dulaglutide, and against dapagliflozin (962), a diabetes drug from an unrelated class. Head-to-head registration is worth noting on its own — a sponsor that registers a comparison against the market leader is accepting a result it cannot control.
What this entry does not cover
Whether orforglipron works better or worse than the injected drugs, and for whom, is a comparison question. GLP1Ledger's orforglipron and tirzepatide comparison takes that up. This entry stops at what the molecule is, who is testing it and what they are testing it for.
The other thing it does not cover is where to get it. Orforglipron is investigational: not approved, not prescribable outside a study, and not a research chemical. There is no lawful consumer source, and a product offered under this name is making a claim that cannot currently be true. Anyone weighing a treatment decision should be talking to a clinician.
Related entries
The peptides that reach the same receptor: semaglutide, the dual GLP-1 and GIP agonist and the one that engages all three receptors. And the name that has no molecule behind it at all, which people often search alongside this one: GLP-3.